- Home
- AOS vs ROIV Comparison
AOS vs ROIV Comparison
Compare AOS & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AOS
- ROIV
- Stock Information
- Founded
- AOS 1874
- ROIV 2014
- Country
- AOS United States
- ROIV United Kingdom
- Employees
- AOS N/A
- ROIV N/A
- Industry
- AOS Industrial Machinery/Components
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- AOS Industrials
- ROIV Health Care
- Exchange
- AOS Nasdaq
- ROIV Nasdaq
- Market Cap
- AOS 9.8B
- ROIV 8.4B
- IPO Year
- AOS N/A
- ROIV N/A
- Fundamental
- Price
- AOS $64.96
- ROIV $9.97
- Analyst Decision
- AOS Buy
- ROIV Strong Buy
- Analyst Count
- AOS 7
- ROIV 6
- Target Price
- AOS $80.86
- ROIV $17.10
- AVG Volume (30 Days)
- AOS 1.4M
- ROIV 7.0M
- Earning Date
- AOS 04-24-2025
- ROIV 02-10-2025
- Dividend Yield
- AOS 2.07%
- ROIV N/A
- EPS Growth
- AOS N/A
- ROIV N/A
- EPS
- AOS 3.63
- ROIV N/A
- Revenue
- AOS $3,818,100,000.00
- ROIV $122,585,000.00
- Revenue This Year
- AOS $1.52
- ROIV N/A
- Revenue Next Year
- AOS $4.90
- ROIV N/A
- P/E Ratio
- AOS $18.07
- ROIV N/A
- Revenue Growth
- AOS N/A
- ROIV 140.04
- 52 Week Low
- AOS $64.55
- ROIV $9.96
- 52 Week High
- AOS $92.45
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- AOS 39.66
- ROIV 42.16
- Support Level
- AOS $65.94
- ROIV $10.63
- Resistance Level
- AOS $68.02
- ROIV $11.42
- Average True Range (ATR)
- AOS 1.24
- ROIV 0.36
- MACD
- AOS -0.15
- ROIV -0.02
- Stochastic Oscillator
- AOS 6.42
- ROIV 7.59
About AOS A.O. Smith Corporation
A.O. Smith manufactures a broad lineup of water heaters, boilers, and water treatment products. The company has two reporting segments: North America (75% of sales) and rest of world (25% of sales). A.O. Smith is the leading manufacturer of water heaters in North America for the residential and commercial markets, with approximately 37% and 54% market share, respectively. Residential water heaters account for Most of North American sales and are distributed equally through wholesale and retail channels. Most of A.O. Smith's international revenue is from China, a market the company entered during the mid-1990s.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.